Wellness company Medifast (NYSE: MED) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 27.6% year on year to $76.38 million. On top of that, next quarter’s revenue guidance ($70 million at the midpoint) was surprisingly good and 3.4% above what analysts were expecting. Its GAAP loss of $0.28 per share was 56.9% above analysts’ consensus estimates.
Is now the time to buy Medifast? Find out by accessing our full research report, it’s free.
Medifast (MED) Q2 CY2026 Highlights:
- Revenue: $76.38 million vs analyst estimates of $72.7 million (27.6% year-on-year decline, 5.1% beat)
- EPS (GAAP): -$0.28 vs analyst estimates of -$0.65 (56.9% beat)
- The company reconfirmed its revenue guidance for the full year of $285 million at the midpoint
- EPS (GAAP) guidance for the full year is $1 at the midpoint, beating analyst estimates by 161%
- Operating Margin: -5.7%, down from -1% in the same quarter last year
- Market Capitalization: $100.8 million
Company Overview
Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE: MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods.
Revenue Growth
A company’s long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years.
With $316.9 million in revenue over the past 12 months, Medifast is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.
As you can see below, Medifast’s revenue declined by 38.7% per year over the last three years, a rough starting point for our analysis.
This quarter, Medifast’s revenue fell by 27.6% year on year to $76.38 million but beat Wall Street’s estimates by 5.1%. Company management is currently guiding for a 21.7% year-on-year decline in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to decline by 17.2% over the next 12 months. it’s hard to get excited about a company that is struggling with demand.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
Cash Is King
Although earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.
Medifast broke even from a free cash flow perspective over the last two years, giving the company limited opportunities to return capital to shareholders.
Key Takeaways from Medifast’s Q2 Results
We were impressed by Medifast’s optimistic EPS guidance for next quarter, which blew past analysts’ expectations. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this quarter featured some important positives. The stock traded up 12.8% to $10.99 immediately following the results.
Sure, Medifast had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).
